title: The diffuse infiltrative lymphocytosis syndrome. Clinical and immunogenetic features in 35 patients.
abstract: OBJECTIVE
  To study the epidemiological, clinical, serological and immunogenetic features of the diffuse infiltrative lymphocytosis syndrome (DILS).
  
  
  METHODS
  Consecutive series of 35 patients with DILS diagnosed from 1992 to 1995 in a cohort of 4100 outpatients infected with HIV-1.
  
  
  METHODS
  Thirty-five individuals with DILS were ascertained from this cohort and followed for 720 patient-months. Clinical, serological and immunogenetic features of these patients were studied and their demographics were compared with the rest of the outpatient population.
  
  
  RESULTS
  DILS was found to be more prevalent in African Americans (60%) than in Caucasians (26%) or Mexican Americans (14%) [odds ratio (OR), 2.32; 95% confidence interval (CI), 1-12-4.81; P = 0.02] and in persons with male-to-male transmission of HIV-1 (71%) (OR, 2.82; 95% CI, 1.29-6.29; P = 0.007). All patients had bilateral parotid gland enlargement. The majority had sicca symptoms. The most common extraglandular sites of disease were lung (31%), muscle (26%), and liver (23%). Four patients had biopsy-proven polymyositis. Thirteen patients met the 1993 Centers for Disease Control and Prevention case definition of AIDS. Sixteen (52%) patients expressed human leukocyte antigen (HLA)-DRS (DRB1*1102), DR6 (DRB1*1301, *1302), or DR7, and 11 (36%) expressed HLA-DR2.
  
  
  CONCLUSIONS
  DILS is more common in African Americans and in persons with male-to-male transmission of HIV-1. HIV-associated polymyositis appears to occur in the setting of DILS.
authors.affiliation: Department of Internal Medicine, University of Texas-Houston Medical School 77030, USA.
authors.forename: S
authors.initials: S
authors.lastname: Kazi
authors.forename: P R
authors.initials: PR
authors.lastname: Cohen
authors.forename: F
authors.initials: F
authors.lastname: Williams
authors.forename: R
authors.initials: R
authors.lastname: Schempp
authors.forename: J D
authors.initials: JD
authors.lastname: Reveille
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D044383:Black People / Q000235:genetics; D015331:Cohort Studies; D005260:Female; D005802:Genes, MHC Class II / Q000235:genetics; D015658:HIV Infections / Q000276:immunology* / Q000635:transmission; D015497:HIV-1; D006801:Humans; D008218:Lymphocytosis / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000208:ethnology / Q000276:immunology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010306:Parotid Gland / Q000473:pathology; D017285:Polymyositis / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D015995:Prevalence; D012466:Salivary Gland Diseases; D012470:Salivary Glands, Minor / Q000473:pathology; D013577:Syndrome; D001741:Black or African American
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone